Pharma BD Deal Intelligence

Novo Nordisk A/S / Deep Apple Therapeutics, Inc.

2025 · Licensing/Option · $812M · Complete

Deep Apple Therapeutics entered a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop and commercialize oral small molecule therapeutics against a novel non-incretin GPCR target for cardiometabolic diseases including obesity. Deep Apple applies its discovery platform combining machine-learning-powered virtual screening with cryo-EM structural biology; total consideration including upfront, research funding and milestones is up to $812 million plus royalties.

Key facts

• Announced Jun 11, 2025
• Deal value $812M
• Deal type Licensing/Option

Related deals

• Novo Nordisk A/S / Emisphere Technologies (2020)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2019)
• Novo Nordisk A/S / Vivtex Inc. (2026)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2021)
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (2022)
• Novo Nordisk A/S / Inversago Pharma (2023)

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Novo Nordisk A/S deals